Celcuity (CELC) Liabilities and Shareholders Equity (2016 - 2026)
Celcuity's (CELC) quarterly Liabilities and Shareholders Equity came in at $466.6 million in Q4 2025, up 90.34% YoY from $245.1 million in Q4 2024, and down 1.98% on a QoQ basis from $476.0 million in Q3 2025.
Celcuity (CELC) Liabilities and Shareholders Equity (2016 - 2026) Analysis & Trends
Celcuity (CELC) has 10 years of Liabilities and Shareholders Equity data on file, last reported at $466.6 million in Q4 2025.
- Quarterly Liabilities and Shareholders Equity rose 90.34% year-over-year to $466.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.3 billion (up 34.58% YoY) and the FY2025 annual result came in at $466.6 million, up 90.34% from the prior year.
- Liabilities and Shareholders Equity eased to $466.6 million in Q4 2025, from $476.0 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $476.0 million in Q3 2025 to a low of $36.4 million in Q1 2021.
- A 5-year average of $182.3 million and a median of $170.3 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
- Annual changes were most pronounced in 2021 — Liabilities and Shareholders Equity soared 563.02% — and 2025, when it slumped 37.24%.
- Tracing CELC's Liabilities and Shareholders Equity over 5 years: stood at $85.9 million in 2021, then jumped by 104.52% to $175.7 million in 2022, then gained by 8.83% to $191.2 million in 2023, then grew by 28.19% to $245.1 million in 2024, then jumped by 90.34% to $466.6 million in 2025.
- The last three Liabilities and Shareholders Equity figures came in at $466.6 million (Q4 2025), $476.0 million (Q3 2025), and $183.6 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Celcuity | 4.50 Bn | 4.50 Bn | - | 828.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 828.22 Mn |
| Dec 31, 2025 | 466.56 Mn |
| Sep 30, 2025 | 476.00 Mn |
| Jun 30, 2025 | 183.59 Mn |
| Mar 31, 2025 | 218.13 Mn |
| Dec 31, 2024 | 245.12 Mn |
| Sep 30, 2024 | 273.04 Mn |
| Jun 30, 2024 | 292.54 Mn |
| Mar 31, 2024 | 188.18 Mn |
| Dec 31, 2023 | 191.22 Mn |
| Sep 30, 2023 | 142.38 Mn |
| Jun 30, 2023 | 153.52 Mn |
| Mar 31, 2023 | 164.87 Mn |
| Dec 31, 2022 | 175.70 Mn |
| Sep 30, 2022 | 65.29 Mn |
| Jun 30, 2022 | 72.35 Mn |
| Mar 31, 2022 | 79.93 Mn |
| Dec 31, 2021 | 85.91 Mn |
| Sep 30, 2021 | 91.84 Mn |
| Jun 30, 2021 | 42.81 Mn |